What drove CPRX's earnings growth in 2024?

Catalyst Pharmaceuticals Inc (CPRX) experienced significant earnings growth in 2024, driven by strong revenue increases across its product portfolio and strategic initiatives:

1. **Revenue Growth**: Total revenues for Q3 and Q4 2024 were $128.7 million and $122.7 million, respectively, reflecting year-over-year increases of 25.3% and 23.2%. This growth was primarily fueled by the performance of key products such as FIRDAPSE® and AGAMREE®.
2. **Product-Specific Performance**: FIRDAPSE®, used for the treatment of Lambert-Eaton myasthenic syndrome, saw a 19.7% year-over-year increase in net product revenue for Q3 2024. AGAMREE®, launched in March 2024, achieved full-year net product revenue of $46 million, surpassing revised guidance.
3. **Strategic Initiatives**: Catalyst Pharmaceuticals' strategic global expansion and exceptional commercial execution contributed to the revenue growth. The company's focus on rare diseases and orphan indications positioned its products well in high-demand markets.
4. **Financial Performance**: The company reported a net income of $163.89 million for 2024, with a diluted EPS of $1.31. This financial performance underscored the effectiveness of Catalyst Pharmaceuticals' operational excellence and strong commercial execution.

In summary, Catalyst Pharmaceuticals' 2024 earnings growth was driven by robust revenue increases from key products, strategic global expansion, and exceptional commercial execution.